Medtronic resolves FDA warning letters over Mounds View, Juncos facilities

Medtronic, Inc. (NYSE:MDT) today announced that the U.S. Food and Drug Administration (FDA) has informed the company that issues noted in two warning letters -- one from November 2009 regarding the company's Mounds View, Minnesota facility and another from June 2009 regarding the company's manufacturing facility in Juncos, Puerto Rico -- have been resolved.

"We are encouraged that the action plans implemented by our teams have resolved the observations identified by the FDA in both warning letters," said William A. Hawkins, chairman and chief executive officer of Medtronic. "We will continue to provide the highest quality products and we are actively working to ensure the changes we have made are appropriately incorporated across all of our global facilities. We have developed a culture of prevention and accountability across our entire enterprise and we will continue to invest aggressively in the continuous improvement of our people, processes and products."

Medtronic received an FDA warning letter following an August 2009 inspection of the company's Mounds View facility, which serves as the headquarters of the Cardiac Rhythm Disease Management business. The company also received an FDA warning letter following a December 2008 inspection of the company's facility in Juncos, which is a manufacturing location for the Neuromodulation, Diabetes and Cardiac Rhythm Disease Management businesses.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
High levels of microplastics found in prostate tumors, possibly linked to take-out food